Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inmune Bio (INMB) Revenue (2021 - 2025)

Inmune Bio (INMB) has disclosed Revenue for 5 consecutive years, with $50000.0 as the latest value for Q1 2025.

  • Quarterly Revenue rose 257.14% to $50000.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $50000.0 through Dec 2025, up 257.14% year-over-year, with the annual reading at $50000.0 for FY2025, 257.14% up from the prior year.
  • Revenue hit $50000.0 in Q1 2025 for Inmune Bio, up from $14000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $163000.0 in Q4 2021 to a low of $4000.0 in Q1 2021.
  • Historically, Revenue has averaged $59538.5 across 5 years, with a median of $43000.0 in 2023.
  • Biggest five-year swings in Revenue: skyrocketed 3975.0% in 2022 and later tumbled 76.69% in 2023.
  • Year by year, Revenue stood at $163000.0 in 2021, then tumbled by 40.49% to $97000.0 in 2022, then crashed by 71.13% to $28000.0 in 2023, then plummeted by 50.0% to $14000.0 in 2024, then soared by 257.14% to $50000.0 in 2025.
  • Business Quant data shows Revenue for INMB at $50000.0 in Q1 2025, $14000.0 in Q1 2024, and $28000.0 in Q4 2023.